Versant backs iCo interim efficacy data

iCo Therapeutics (TSX-V:ICO) reported interim efficacy data at a medical conference over the weekend from a few patients in its 15-patient Phase 1 diabetic macular edema trial testing its antisense drug iCo-007. Versant Partners analyst Doug Loe writes that the case-study data “showed solid evidence of iCo-007 impact on retinal thickness/macular edema at six months [...]

Versant starts iCo at “buy”

Versant Partners has initiated coverage of iCo Therapeutics (TSX-Venture:ICO) with a “buy” rating and 12-month price target of $1.80.  The shares closed Monday at 59 cents. iCo is an early-stage drug developer focused on in-licensing preclinical or Phase 1 drugs targeting ocular diseases.  Its lead antisense drug iCo-007 is in Phase 1/2 testing for diabetic [...]